Liver Cancer Trial, Recruiting NCT06125769 Sponsor: Azienda Sanitaria Ospedaliera Condition: Liver Cancer
Back to Liver Cancer

Liver Cancer Trial, Recruiting

NCT06125769
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with perihilar cholangiocarcinoma (a type of bile duct cancer near the liver), confirmed through specific tests such as tissue sampling, a blood marker test, or imaging scans showing a blockage that looks cancerous
  • People whose cancer cannot be surgically removed, or whose cancer developed in the setting of a condition called primary sclerosing cholangitis (PSC) and may be removable
  • People whose cancer has not spread into major blood vessels, outside the liver area, or into nearby lymph nodes
  • People with no cancer spread outside the liver region
  • People whose tumor measures 3 centimetres or less across at its widest point
  • People who were first diagnosed with this cancer at least six months before joining the trial
  • People who have received at least six months of standard chemotherapy treatment, with results showing the cancer has stayed stable or partially responded to treatment

Who may not be able to join:

  • People with an infection that cannot be controlled
  • People who have previously had radiation therapy or chemotherapy (confirm with trial site regarding chemotherapy, given inclusion criteria also require prior chemotherapy)
  • People who have previously had surgery on the bile ducts, or where surgery was attempted
  • People whose tumor is larger than 3 centimetres across
  • People who have cancer that has spread within the liver, or who have a related type of bile duct cancer that starts inside the liver (intrahepatic cholangiocarcinoma)
  • People with current or past evidence of cancer spread outside the liver area
  • People whose tissue sample was taken through the skin using a needle guided by ultrasound or similar imaging (a type of biopsy called percutaneous FNA)
  • People who have had a previous cancer, unless it was fully treated more than 5 years ago with no return of the cancer
  • People with substance use issues, or medical, psychological, or social circumstances that could affect participation in the study
  • Women who are pregnant or breastfeeding
  • People for whom liver transplantation surgery would be medically unsafe

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Enrico Gringeri, Prof., Azienda Ospedale Università di Padova

Phone: +39 0498218547

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Azienda Sanitaria Ospedaliera
Registry
ClinicalTrials.gov
Start date
15 January 2024
Est. completion
1 November 2028

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

Overall Survival (OS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov